Pharmaceutical companies are investing in a lesser-known form of cholesterol, which they believe could be the key to developing their next blockbuster heart medications. This emerging focus on cholesterol aims to address heart disease more effectively and improve patient outcomes.
Recent advancements in gene editing techniques, particularly the silencing of the PCSK9 gene, have shown promising clinical results in humans. These innovations may pave the way for groundbreaking treatments that could rewrite the future of heart health.